Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Mirum Pharmaceuticals and keeping the price target at $130.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight Mirum’s strong current performance and future growth prospects. The analyst points to robust revenue momentum, with 2025 sales and Livmarli-driven growth outpacing guidance, and argues that management’s 2026 outlook appears cautious in light of ongoing commercial strength and the expansion of Livmarli into a broader, more adult-focused tablet market.
He further emphasizes that the tablet formulation should support better adherence and wider adoption, potentially lifting sales beyond current forecasts and benefiting from a key EXPAND trial readout expected in late 2026. In addition, Ramakanth underscores a catalyst-rich pipeline, with multiple late-stage studies across volixibat, brelovitug, Livmarli, and MRM-3379 that, if successful, could translate into up to four new approvals and meaningful incremental revenue through 2027, reinforcing the favorable risk‑reward profile of the stock.
According to TipRanks, Ramakanth is a 5-star analyst with an average return of 16.3% and a 41.80% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Mirum Pharmaceuticals, and Pyxis Oncology.
In another report released today, Morgan Stanley also reiterated a Buy rating on the stock with a $130.00 price target.